看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
& J8 O" y: Y2 K1 T
. _. `$ N: b( K$ `, |3 d+ U- r# R
Currently available feasibility data for possible combination strategies.
' X- {1 |9 \, Y' t————————————————————————————————
0 K' L+ _' D. V- WCombination Feasibility according to preliminary data # t: Q& v O4 }, t |: h }
——————————————————————————————————
6 \( p. w% y8 l: ], f) ?) OBevacizumab + sorafenib Yes, reduced dose
6 |' G0 {: ]+ V4 [2 lBevacizumab + sunitinib† No
" y* |* g: w& m% LBevacizumab + temsirolimus Yes
: q( B$ Z, @4 ?5 [- {* nBevacizumab + everolimus Yes
. x' k$ \) ^: k% c kSorafenib + sunitinib ? ; L7 t/ R4 L$ K" p' m/ f ^
Sorafenib + temsirolimus Yes, reduced dose
5 I1 C9 f* S' ~- gSorafenib + everolimus Yes, reduced dose " Y& G) c% _4 P, x
Sunitinib + temsirolimus† No
4 g& o8 F: V* }5 F) n6 Y$ ^/ b% |# R RSunitinib + everolimus ?
3 D7 ] O) N0 y$ t! _Temsirolimus + everolimus ?
$ n$ y* w4 k6 U————————————————————
4 @/ X) c: e. g4 \9 t2 T# t†Led to US FDA warning.; P) o& f! y/ m0 Q7 p( o
?: As yet unattempted combination.
4 s& m9 ]) k+ Z! R# O0 ~ |